LIXT Lixte Biotechnology, Inc.: Accounting Value per Share

Public company logo of Lixte Biotechnology Holdings Inc. (LIXT)

The BVPS chart provided by the GURU.Markets portal demonstrates equity dynamics, while the 0.68 metric confirms the current level. Lixte Biotechnology (LIXT) seeks expansion through the development of the LB-100 platform to enhance chemotherapy. Management focuses on creating medical breakthroughs while skillfully attracting investment. Stable management adheres to R&D plans, maintaining the trust of specialized funds regarding liquidity management.

LIXT - Lixte Biotechnology Holdings Inc. Book Value of One Share over the range 07/04/2022 - 07/06/2026

Summary analytical data breakdowns for lixte.com (LIXT)

- price and consensus price forecast:
Stock Quotes Lixte Biotechnology Holdings|LIXT - Broker Consensus Forecast
- market capitalization data:
Market Valuation Lixte Biotechnology Holdings, Inc.|LIXT - Aggregate Business Value
- book capitalization data:
Book Value per Share Lixte Biotechnology|LIXT - Book Value of Business|Market Capitalization to Book Value Ratio lixte.com|LIXT - Company Assets
- debt and liquidity data:
Debt to Equity Lixte Biotechnology|LIXT - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Lixte Biotechnology Holdings, Inc.|LIXT - Company Cumulative Debt|Debt to Book Capitalization Ratio Lixte Biotechnology Holdings, Inc.
Fundamental company valuation:LIXT Lixte Biotechnology Holdings
Manufactured product of lixte.com

Proprietary oncology inhibitors and long-term partnerships with pharma behemoths provide a sustainable foundation for the capitalization of Lixte Biotechnology (LIXT). Book value per share data reflects the difference between total assets and liabilities, allowing investors to use this chart to assess the actual volume of the company's equity per share and track the factual dynamics of shareholder value.

Competitors of Lixte Biotechnology (LIXT)

Incyte Corp. (INCY) - Accounting Value per Share|HUTCHMED Corp (HCM) - Equity per Share|NUVB - Accounting Value per Share|dayonebio.com (DAWN) - Book Price of a Share|Monopar Therapeutics Inc. - Book Value per Share|Book Value of One Share Inhibrx|I-Mab - Book Value per Share|Net Asset Value per Share FENC (Fennec)|HRTX - Net Assets per Single Share|Equity per Share nuvectis.com NVCT|CHRS (Coherus Biosciences) - Book Value per Share|CRBP: Net Asset Value per Share|Net Assets per Single Share cardiffoncology.com CRDF|BeyondSpring Inc (BYSI) - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share CTXR|Net Assets per Single Share Cellectar Biosciences, Inc. (CLRB)|Net Assets per Single Share BioLineRx Ltd BLRX|Accounting Value per Share Can-Fite BioPharma, Ltd.|Aprea Therapeutics Inc. - Accounting Value of a Share|KZIA (Kazia) - Net Assets per Single Share|SLXN: Net Asset Value per Share|Net Assets per Single Share nucana.com|Chimerix Inc. (CMRX) - Equity per Share|Book Value per Share CYCC|Accounting Value per Share GTHX|Kronos Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share KTRA (kintara.com)|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share